44,681 Shares in Pfizer Inc. $PFE Purchased by Integrated Financial Solutions Inc.

Integrated Financial Solutions Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 44,681 shares of the biopharmaceutical company’s stock, valued at approximately $1,083,000. Pfizer makes up about 0.9% of Integrated Financial Solutions Inc.’s portfolio, making the stock its 15th biggest position.

Other hedge funds also recently bought and sold shares of the company. Fiduciary Alliance LLC lifted its holdings in shares of Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after acquiring an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Pfizer in the third quarter worth about $3,019,000. Money Concepts Capital Corp grew its holdings in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares in the last quarter. Vista Investment Partners LLC increased its position in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. raised its holdings in shares of Pfizer by 76.4% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $27.61 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The stock’s 50-day simple moving average is $26.13 and its 200-day simple moving average is $25.41. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $156.97 billion, a price-to-earnings ratio of 20.30 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business’s revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $0.63 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is presently 126.47%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Finally, Royal Bank Of Canada started coverage on Pfizer in a research note on Tuesday. They issued an “underperform” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $27.70.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.